Top Markets
#1 DogBull DogBull +105.06%
#2 ADO Protocol ADO Protocol +49.91%
#3 Siacoin Siacoin +46.86%
#4 MarsCoin MarsCoin +36.68%
#5 The Bitcoin Bull The Bitcoin Bull +29.10%
#6 Glidr Glidr +24.16%
#7 Ontology Gas Ontology Gas +23.77%
#8 Useless Coin Useless Coin +22.27%
#9 UnifAI Network UnifAI Network +21.53%
#10 Falcon Finance Falcon Finance +17.11%
Coin of the day
DogBull DogBull
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Rangering i aksjer #15974
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Aksjekurs
$15.42
Markedsverdi
$320.83M
Endring (1 dag)
-1.52%
Endring (1 år)
40.67%
Land
IT
Handel Newron Pharmaceuticals S.p.A. (NP5)

Kategori

Healthcare
Inntekter for Newron Pharmaceuticals S.p.A. (NP5)
Inntekter i Sep 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Newron Pharmaceuticals S.p.A. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Newron Pharmaceuticals S.p.A. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH